Here are five things to know:
1. Cerapedics will offer its proprietary synthetic small peptide, P-15, technology and DSM will provide its regenerative materials portfolio.
2. DSM has a bioceramic platform featuring a carbonated apatite matrix.
3. Cerapedics’ P-15 technology promotes bone growth from cell attraction to attachment to activation.
4. Cerapedics’ i-FACTOR Peptide Enhanced Bone Graft has been on the U.S. market since 2008. i-FACTOR was approved for anterior cervical discectomy and fusion in 2015.
5. The next-generation technology will focus on the lumbar spine.
More articles on devices:
DePuy Synthes launches 3-D circular fixation device: 5 insights
Drs. Nick Theodore, Ali Bydon, Kade Huntsman perform 1st surgeries using Globus Medical’s ExcelsiusGPS: 5 takeaways
Medicrea unveils UNiD HUB in Europe: 5 insights
